Sanofi launches dedicated vaccines mRNA Center of Excellence
29 Juni 2021 - 10:00AM
Sanofi launches
dedicated
vaccines mRNA Center of
Excellence
- Approximately €400million investment annually to accelerate
end-to-end R&D of next-generation vaccines, fully financed
through resource reallocation
- Focus on innovating mRNA vaccines beyond pandemic to routine
use in diseases with high unmet need
- Expected minimum of six clinical candidates by 2025
PARIS
– June
29, 2021 -
Sanofi will invest approximately €400 million annually in a
first-of-its kind vaccines mRNA Center of Excellence. The Center
will work to accelerate the development and delivery of
next-generation vaccines by bringing together approximately 400
dedicated employees integrating end-to-end mRNA vaccine
capabilities with dedicated R&D, digital, and chemistry,
manufacturing and controls (CMC) teams across sites at Cambridge,
MA (US) and Marcy l’Etoile, Lyon
(France). “During
the COVID-19 pandemic, mRNA technologies demonstrated potential to
deliver new vaccines faster than ever before. However, key areas of
innovation such as thermostability and tolerability improvements
will be critical to unlock the applications of mRNA in routine
vaccination against a broader set of infectious diseases and across
all ages. The Sanofi mRNA vaccines Center of Excellence aims to
lead the field in this next chapter of vaccine innovation,” said
Jean-Francois Toussaint, Global Head of Research and Development,
Sanofi Pasteur.
The Center of Excellence will enable
acceleration of the vaccines mRNA portfolio developed through the
Translate Bio collaboration established in 2018 and expanded in
2020.
“This massive new investment clearly puts us in
the race to develop next-generation vaccines where mRNA
technologies can have greatest impact.” said Thomas Triomphe,
Executive Vice President, Global Head of Sanofi Pasteur. “While
mRNA won’t be the solution for every infectious disease, its
translation into routine prevention could have immense impact for
many unmet public health needs. It now becomes a critical new
technology in our comprehensive vaccines toolbox, one which could
help reinvent health protection in the future.”
Sanofi is committed to rapidly establishing an
industry-competitive mRNA platform and is working with our partners
and all relevant stakeholders, internally and externally, to
achieve this objective.
About Sanofi Sanofi is dedicated to
supporting people through their health challenges. We are a global
biopharmaceutical company focused on human health. We prevent
illness with vaccines, provide innovative treatments to fight pain
and ease suffering. We stand by the few who suffer from rare
diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is
transforming scientific innovation into healthcare solutions around
the globe. |
Media Relations ContactsAshleigh KossTel: +1 (908)
205-2572ashleigh.koss@sanofi.com Sandrine GuendoulTel.: +33
(0)6 25 09 14 25sandrine.guendoul@sanofi.com |
Investor Relations Contacts ParisEva
Schaefer-JansenArnaud DelepineNathalie Pham Investor
Relations Contacts North AmericaFelix LauscherFara
BerkowitzSuzanne Greco IR main line:Tel.: +33 (0)1 53 77 45
45investor.relations@sanofi.comhttps://www.sanofi.com/en/investors/contact
|
Sanofi Forward-Looking StatementsThis press
release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical
facts. These statements include projections and estimates and their
underlying assumptions, statements regarding plans, objectives,
intentions and expectations with respect to future financial
results, events, operations, services, product development and
potential, and statements regarding future performance.
Forward-looking statements are generally identified by the words
“expects”, “anticipates”, “believes”, “intends”, “estimates”,
“plans” and similar expressions. Although Sanofi’s management
believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various
risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual
results and developments to differ materially from those expressed
in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, the uncertainties inherent in research and development,
future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA,
regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the fact that product candidates if
approved may not be commercially successful, the future approval
and commercial success of therapeutic alternatives, Sanofi’s
ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks
associated with intellectual property and any related pending or
future litigation and the ultimate outcome of such litigation,
trends in exchange rates and prevailing interest rates, volatile
economic and market conditions, cost containment initiatives and
subsequent changes thereto, and the impact that COVID-19 will have
on us, our customers, suppliers, vendors, and other business
partners, and the financial condition of any one of them, as well
as on our employees and on the global economy as a whole. Any
material effect of COVID-19 on any of the foregoing could also
adversely impact us. This situation is changing rapidly and
additional impacts may arise of which we are not currently aware
and may exacerbate other previously identified risks. The risks and
uncertainties also include the uncertainties discussed or
identified in the public filings with the SEC and the AMF made by
Sanofi, including those listed under “Risk Factors” and “Cautionary
Statement Regarding Forward-Looking Statements” in Sanofi’s annual
report on Form 20-F for the year ended December 31, 2020. Other
than as required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or
statements. |
Sanofi (EU:SAN)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Sanofi (EU:SAN)
Historical Stock Chart
Von Apr 2023 bis Apr 2024